Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.
|Videos|June 13, 2016
Use of Liquid Biopsies for Patients With EGFR-Mutated NSCLC
Author(s)Heather A. Wakelee, MD
Heather A. Wakelee, MD, discusses a study utilizing liquid biopsies in patients with non-small cell lung cancer who harbor EGFR mutations.
Advertisement
Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses a study utilizing liquid biopsies in patients with nonsmall cell lung cancer who harborEGFR
Advertisement
Related to this article
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5